Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial
29 Jul, 2021
Authors: C. Kityo, E. White, A. Turkova, H.A Mujuru, I. Nankya, B. Wynne, S. Ali, A. Kekitiinwa, A. Lugemwa, E. Kaudha, A. Liberty, H. Cassim, M. Archary, M. Cotton, L.…
Read More
A randomised comparison of DTG-based ART vs Standard of Care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial
21 Jul, 2021
Authors: LugemwaA, Mujuru H, Wynne B, Violari A, Kekitiinwa R.A, Kityo M.C, Archary M, Variava E, Sarfati T, Shakeshaft C, Turner R, Nathoo R, Chidziva E, Atwine L, Ramsagar N, Liberty…
Read More
Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial
21 Jul, 2021
Authors: Turkova A, Kekitiinwa A, White E, Mumbiro V, Khauda E, Liberty A, Dobbels E, Ahimbisibwe M.G, Moloantoa T, Atwine T, Kanjanavanit S, Mosia R.N, Puthanakit T, Smit T, Kobbe R,…
Read More
Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial
21 Jul, 2021
Authors: Turkova A, Kityo C, Mujuru A.H, Variava E, Kekitiinwa A, Lugemwa A, Barlow-Mosha L, Ngampiyaskul C, Zuidewind P, Puthanakit T, Mngqbisa R, Behuhuma O.N, Kataike H, Musoro G, Nandudu A,…
Read More
Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial
21 Jul, 2021
Authors: Kityo C, White E, Turkova A, Mujuru A.H, Nankya I, Wynne B, Ali S, Kekitiinwa A, Lugemwa A, Kaudha E, Liberty A, Cassim H, Archary M, Cotton M, Barlow-Mosha L,…
Read More
Once daily integrase inhibitor (INSTI) with boosted darunavir is non-inferior to standard of care in virologically suppressed children – Week 48 results of the SMILE Penta-17 Trial
19 Jul, 2021
Authors: Compagnucci A, Chan M, Saïdi Y, Cressey T, Bamford A, Riault Y, Coelho A, Nolan A, Chalermpantmetagul S, Amuge P, Musiime V, Violari A, Cotton M, Kekitiinwa A, Kaudha…
Read More
Once-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non- Inferior to Standard of Care in Virogically Suppressed Children, Week 48 Results of the SMILE PENTA-17 Trial
19 Jul, 2021
Authors: Compagnucci A , Chan M , Saïdi Y , Cressey T , Bamford A , Riault Y , Coelho A , Nolan A ,Chalermpantmetagul S , Amuge P ,…
Read More
Early ART initiation during infancy preserves natural killer cells in young European adolescents living with HIV (CARMA cohort)
09 Jul, 2021
Authors: M Doria, S Zicari, N Cotugno, S Domínguez-Rodríguez, A Ruggiero, GR Pascucci, A Tagarro, PR Conejo, E Nastouli, K Gärtner, M Cameron, B Richardson, Ce Foster, SL Williams, S Rinaldi, AD Rossi, C Giaquinto, P Rossi, S Pahwa, P Palma, for the EPIICAL consortium Published in: Journal of the…
Read More
Brain MRI and neurocognitive characteristics of children with perinatal HIV infection in Russia: a retrospective cross-sectional study
03 Jun, 2021
Authors: MB. García, L. Okhonskaya, E. Voronin, V. Rozenberg, M. Titova, T. Kovalenko, A. Turkova, IJ. Collins, S. Crichton, C. Velo Higueras, MI. Gonzalez-Tomé, JT. Ramos-Amador, AMD. Aragón, on behalf of the REACH/EPPICC research groups Published in: ESPID Abstract Method: Retrospective…
Read More
Because we all have to grow up”: supporting adolescents in Uganda to develop core competencies to transition towards managing their HIV more independently
22 Mar, 2021
Authors: Chloe Lanyon, Janet Seeley, Stella Namukwaya, Victor Musiime, Sara Paparini, Helen Nakyambadde, Christine Matama, Anna Turkova, Sarah Bernays Published in: Journal of International Aids Society Abstract Introduction: Sustaining optimal adherence is the major challenge facing adolescents…
Read More
DOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI- BASED ART IN CHILDREN AND ADOLESCENTS
11 Mar, 2021
Authors: Anna Turkova1, for the ODYSSEY/PENTA-20 Trial Team Published in: CROI 2021 Abstract: ODYSSEY is an international multi-centre randomised non-inferiority trial evaluating dolutegravir (DTG) + 2NRTIs versus standard-of-care (SOC)…
Read More
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
19 Feb, 2021
Authors: Cecilia L. Moore, Anna Turkova , Hilda Mujuru , Adeodata Kekitiinwa, Abbas Lugemwa, Cissy M. Kityo, Linda N. Barlow-Mosha, et al, ODYSSEY trial team Published in: BMC Infectious Diseases…
Read More
A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200mg in pregnant women living with HIV
29 Dec, 2020
Authors: Vera E. Bukkems, Teun M. Post, Angela P. Colbers, David M. Burger, Elin M. Svensson Published in: American Society for Clinical Pharmacology and Therapeutics Abstract: Once‐daily two 600mg tablets…
Read More
Cascade of care in children and adolescents with HIV in Russian Federation
10 Dec, 2020
Author: Anna Turkova, Evgeny Voronin, Yulia Plotnikova, Anna Samarina, Edith Milanzi, Vladimir Rozenberg, Liubov Okhonskaia, Inga Latysheva, Aleksey Plynsky, Elena Fertikh, Siobhan Crichton, Charlotte Jackson, Ali Judd, Intira J Collins,…
Read More
Pediatric dolutegravir (DTG) dosing recommendations derived from combined P1093 and ODYSSEY Population Pharmacokinetic analysis
04 Dec, 2020
Authors: Singh R, Baker M, Thapar M, Gibb D, Turkova A, Ford D, Ruel T, Wiznia A, Farhad M, Alvero C, Green J, Bollen P, Colbers A, Burger D, Acosta…
Read More
COVID and HIV: Psychological impact and awareness of COVID-19 in young people with HIV
30 Oct, 2020
Authors: S. Bernardi1, E. Mozzo, M. Di Pastena, F. Leone, C. Novello, A. Oletto, N. Cotugno, P. Zangari, P. Palma, V. Santilli, P. Palma, O. Rampon, C. Giaquinto Published in:…
Read More
The effect of pregnancy on the pharmacokinetics of total and unbound Dolutegravir and its main metabolite in women living with Human Immunodeficiency Virus
07 Sep, 2020
Authors: Bollen P, Freriksen J, Konopnicki D, Weizsäcker K , et al; on behalf of the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women Network Published in: Clin infect Dis. 2020;26.ciaa006…
Read More
Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study
07 Sep, 2020
Authors: Bukkems V, Necsoi C, Hidalgo Tenorio C, et al. PANNA Network Published in: Clin infect Dis. 2020; 24;ciaa488. Abstract This phase-IV study investigated the influence of pregnancy on the pharmacokinetics…
Read More